Do you want to read an article? Please log in or register.
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy
Genitourinary CancerNuclear Medicine
COMMENTED
Related content
Skin Cancer
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Eur J Cancer
Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L
doi: 10.1016/j.ejca.2024.113976
ESMO 2024
Genitourinary Cancer
223Ra followed by 177Lu-PSMA was clinically feasible in heavily pretreated patients with mCRPC in clinical practice
COMMENTED
Nuclear Medicine
A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
J Nucl Med
Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J, Weber WA, Fendler WP, Hofman MS, Krause BJ, Brackman M, Kpamegan E, Ghebremariam S, Benson T, Catafau AM, Kendi AT
doi: 10.2967/jnumed.122.265077
APCCC 2024
Genitourinary Cancer
Patient selection for radioligand therapy
Multiple Myeloma (MM)
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
Blood
Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona R, Girgis S, Miao X, Uhlar C, Chastain K, Garfall A
doi: 10.1182/blood.2023023616
Gastrointestinal Cancer
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study
Lancet Oncol
Dawson LA, Ringash J, Fairchild A, Stos P, Dennis K, Mahmud A, Stuckless TL, Vincent F, Roberge D, Follwell M, Wong RKW, Jonker DJ, Knox JJ, Zimmermann C, Wong P, Barry AS, Gaudet M, Wong RKS, Purdie TG, Tu D, O'Callaghan CJ
doi: 10.1016/S1470-2045(24)00438-8
COMMENTED
Genitourinary CancerNuclear Medicine
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
★ 3
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Lancet
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K, PSMAfore Investigators
doi: 10.1016/S0140-6736(24)01653-2
Genitourinary Cancer
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
EJNMMI Phys
Grob D, Privé BM, Muselaers CHJ, Mehra N, Nagarajah J, Konijnenberg MW, Peters SMB
doi: 10.1186/s40658-024-00636-0
ASCO 2024
Genitourinary Cancer